A 24-week multicentre, randomised, open-label, parallel-group study comparing the efficacy and safety of ixekizumab to fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis na ïve to systemic treatment.

CONCLUSIONS: Ixekizumab was superior in inducing PASI 75/90/100, sPGA(0,1), and DLQI(0,1) responses at week 24 compared to methotrexate and FAE. Safety profiles for all treatments were consistent with prior studies. This article is protected by copyright. All rights reserved. PMID: 31376153 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31376153?dopt=Abstract

Source: The British Journal of Dermatology - August 2, 2019 Category: Dermatology Authors: Reich K, Augustin M, Thaçi D, Pinter A, Leutz A, Henneges C, Schneider E, Schacht A, Dossenbach M, Mrowietz U Tags: Br J Dermatol Source Type: research